Trial · NCT05533164
Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Experiencing a PMR Relapse
NCT05533164, Phase 3, Active not recruiting, Sint Maartenskliniek
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Experiencing a PMR Relapse. Trials, record NCT05533164. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT05533164
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Experiencing a PMR Relapse
- NCT number
- NCT05533164
- Status
- Active not recruiting
- Phases
- Phase 3
- Enrollment
- 174 participants, estimated
- Lead sponsor
- Sint Maartenskliniek
- Conditions
- Polymyalgia Rheumatica
- Interventions
- Rituximab, Placebo
- First posted
- 2022-09-08
- Last updated
- 2026-02-04
Source ClinicalTrials.gov
Registered outcomes9
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Between group difference in percentage of patients in glucocorticoid-free remission | At week 52 | Between group difference in percentage of patients in glucocorticoid-free remission (PMR activity score \< 10) at week 52 |
| Secondary | Percentage of patients in glucocorticoid-free remission | 21 weeks | Percentage of patients in glucocorticoid-free remission |
| Secondary | Percentage of patients with glucocorticoid dose of ≤5mg/day | 52 weeks | Percentage of patients with glucocorticoid dose of ≤5mg/day |
| Secondary | Number of relapses | 52 weeks | Number of relapses |
| Secondary | Time to glucocorticoid-free remission | 52 weeks | Time to glucocorticoid-free remission in days during the study period |
| Secondary | Time to relapse | 52 weeks | Time to relapse in days during the study period |
| Secondary | Cumulative glucocorticoid dose | 52 weeks | Cumulative glucocorticoid dose |
| Secondary | Percentage of patients needing RTX/Placebo retreatment | 52 weeks | Percentage of patients needing RTX/Placebo retreatment |
| Secondary | Adverse events | 52 weeks | Adverse events |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 39400109 | DERIVED |
Source PubMed
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT05533164
GET https://conductscience.org/api/trials/v1/NCT05533164/registered